SCHEMBL7129484

SCHEMBL7129484

Brc1ccc([CH]/C=C/c2ccc(Br)cc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 3/20 0.45
ALDH1A1 P00352 2/20 0.45
HPGD P15428 2/20 0.45
KDM4E B2RXH2 1/20 0.45
RAB9A P51151 1/20 0.45
CYP2A6 P11509 1/20 0.42
SLC5A1 P13866 1/20 0.40
SLC5A2 P31639 1/20 0.40
CYP2D6 P10635 3/20 0.39
MAPT P10636 3/20 0.39
MEN1 O00255 2/20 0.39
CYP3A4 P08684 2/20 0.39
CYP2C9 P11712 2/20 0.39
KMT2A Q03164 2/20 0.39
TUBB4A P04350 1/20 0.39
TUBB P07437 1/20 0.39
TUBA3C P0DPH7 1/20 0.39
TUBA1B P68363 1/20 0.39
TUBA4A P68366 1/20 0.39
TUBB4B P68371 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3847986 0.91 MAOB (0.54) CYP2C19ALDH1A1HPGDKDM4ERAB9A
SCHEMBL3847989 0.91 MAOB (0.54) CYP2C19ALDH1A1HPGDKDM4ERAB9A
SCHEMBL7121267 0.89 NFE2L2 (0.45) CYP2C19ALDH1A1HPGDKDM4ERAB9A
SCHEMBL7121300 0.89 HDAC2 (0.46) CYP2C19ALDH1A1HPGDKDM4ERAB9A
SCHEMBL7130620 0.89 HDAC2 (0.46) CYP2C19ALDH1A1HPGDKDM4ERAB9A
SCHEMBL2622600 0.86 APP (0.50) CYP2C19ALDH1A1HPGDKDM4ERAB9A
SCHEMBL10137941 0.83 APP (0.55) CYP2C19ALDH1A1HPGDKDM4ERAB9A
SCHEMBL1882464 0.80 ALDH1A1 (0.61) CYP2C19ALDH1A1HPGDKDM4ERAB9A
SCHEMBL9679616 0.80 ALDH1A1 (0.61) CYP2C19ALDH1A1HPGDKDM4ERAB9A
SCHEMBL391122 0.80 ALDH1A1 (0.61) CYP2C19ALDH1A1HPGDKDM4ERAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6667346-B2 Administration of a radioprotective alpha, beta unsaturated aryl sulfone compound to a patient prior to anticancer radiotherapy reduces cytotoxic side effects of radiation on normal cells TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2003-12-23 US disclosed